Get the Stockscreener App
20.36
2.21%
-0.46
After Hours:
20.35
-0.010
-0.05%
Catalyst Pharmaceuticals Inc stock is traded at $20.36, with a volume of 1.25M.
It is down -2.21% in the last 24 hours and up +3.14% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$20.82
Open:
$20.99
24h Volume:
1.25M
Relative Volume:
0.84
Market Cap:
$2.49B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
17.25
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
-2.30%
1M Performance:
+3.14%
6M Performance:
-5.08%
1Y Performance:
+2.26%
1-Day Range:
$20.26
$20.99
1-Week Range:
$20.26
$21.22
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.36 | 2.55B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Using Ichimoku Cloud for Catalyst Pharmaceuticals Inc. technicalsWatch List & Consistent Growth Equity Picks - newser.com
Published on: 2025-10-10 04:19:27 - newser.com
Will earnings trigger a reversal in Catalyst Pharmaceuticals Inc.Portfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewswire
Catalyst Pharmaceuticals to Present Research on Duchenne Muscular Dystrophy and Lambert Eaton Myasthenic Syndrome at Upcoming Scientific Conferences - Quiver Quantitative
3 Presentations: Catalyst Pharmaceuticals to present DMD & LEMS data at Oct 2025 conferences - Stock Titan
Real time breakdown of Catalyst Pharmaceuticals Inc. stock performance2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Published on: 2025-10-09 06:27:04 - newser.com
Catalyst Pharmaceuticals Delivers Growth But Faces Narrow Pipeline Risk - Finimize
Published on: 2025-10-09 00:54:28 - newser.com
Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals - Barchart.com
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)? - MSN
Will Catalyst Pharmaceuticals Inc. rebound enough to break evenTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Published on: 2025-10-06 05:08:49 - newser.com
Detecting price anomalies in Catalyst Pharmaceuticals Inc. with AIEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
A Closer Look at Catalyst Pharmaceuticals (CPRX) Valuation as Shares Remain Steady This Week - Sahm
Order flow analysis tools used on Catalyst Pharmaceuticals Inc.Weekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Wealth Enhancement Advisory Services LLC Lowers Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - Defense World
Why Catalyst Pharmaceuticals Inc. (CN2) stock could break out in 2025July 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Catalyst Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
What macro factors could drive Catalyst Pharmaceuticals Inc. (CN2) stock higherPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Published on: 2025-10-03 06:09:02 - newser.com
Using flow based indicators on Catalyst Pharmaceuticals Inc.2025 Big Picture & Daily Stock Trend Watchlist - newser.com
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsGold Moves & Daily Entry Point Alerts - newser.com
Historical volatility pattern of Catalyst Pharmaceuticals Inc. visualizedJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - The Manila Times
Share Repurchase Program Initiated by Catalyst Pharmaceuticals (NASDAQ:CPRX) Board of Directors - Defense World
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - GlobeNewswire
Catalyst Pharma Announces $200M Share Repurchase Program - TipRanks
Catalyst Pharmaceuticals, Inc. authorizes a Buyback Plan. - MarketScreener
Catalyst Pharmaceuticals, Inc. announces an Equity Buyback for $200 million worth of its shares. - MarketScreener
Catalyst Pharma Announce New Share Repurchase Program Of $200 Mln - Nasdaq
Catalyst Pharmaceuticals Approves $200 Million Share Repurchase Program - MarketScreener
Catalyst Pharmaceuticals authorizes $200 million share buyback program By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals authorizes $200 million share buyback program - Investing.com
$200M Share Buyback: Catalyst Pharmaceuticals Taps Into $650M Cash Reserve for Stockholder Returns - Stock Titan
Developing predictive dashboards with Catalyst Pharmaceuticals Inc. dataJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elsbernd Brian | Chief Compliance/Legal Officer |
Sep 08 '25 |
Sale |
20.30 |
30,000 |
609,000 |
271,039 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):